Zymeworks (NYSE:ZYME) and its collaborator BeiGene have announced the dosing of the first patient with zanidatamab (ZW25) in South Korea–based HERIZON-GEA-01 study. The study will focus on patients with advanced or metastatic HER2-positive gastroesophageal adenocarcinomas. As a result of the development, Zymeworks will receive an $8 million development milestone payment from BeiGene. Zymeworks and BeiGene plan to…